The Evolut FX+ TAVR system, which already received FDA approval in March, was designed with improved coronary access in mind. One cardiologist described the device as a "significant step forward" for patients with heart disease. 

Significant fluctuations in PET and CT reimbursement rates have made it especially challenging to keep up with this complex topic. We spoke to an expert to learn more.

Many Americans have never heard of peripheral artery disease or other common vascular conditions. In fact, a vast majority are not sure what vascular surgeons do.

Four leading cardiothoracic surgery societies have joined forces in the name of developing clinical practice guidelines that are more thorough and consistent.

While production is relatively unchanged compared to the previous year, compensation is up significantly for cardiovascular surgeons in the United States. 

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

The two newly approved technologies are used together to help visualize cardiac ablation procedures performed with Boston Scientific’s Farapulse pulsed field ablation system.

Baroreflex activation therapy with the Barostim device from CVRx has received new CPT codes from the American Medical Association. The codes go into effect in January 2026.